Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.63 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699046 | 0.73 | SCN9A (1.00) | SCN9AGRIA1CACNG8CACNG2NPC1 | |
| SCHEMBL1384144 | 0.73 | SCN4A (0.53) | SCN9A | |
| SCHEMBL12130054 | 0.70 | GRIA1 (0.74) | SCN9AGRIA1CACNG8CACNG2 | |
| SCHEMBL27646780 | 0.69 | ESR1 (0.61) | SCN9AGRIA1CACNG8CACNG2NPC1 | |
| SCHEMBL16699310 | 0.68 | SCN9A (0.76) | SCN9AGRIA1CACNG8CACNG2KCNH2 | |
| SCHEMBL16698759 | 0.68 | SCN9A (0.70) | SCN9AGRIA1CACNG8CACNG2NPC1 | |
| SCHEMBL5581280 | 0.68 | GRIA1 (0.78) | SCN9AGRIA1CACNG8CACNG2RAB9A | |
| SCHEMBL22522303 | 0.67 | GRIA1 (0.60) | SCN9AGRIA1CACNG8CACNG2NPC1 | |
| SCHEMBL22522532 | 0.67 | GRIA1 (0.77) | SCN9AGRIA1CACNG8CACNG2NPC1 | |
| SCHEMBL22522309 | 0.67 | GRIA1 (0.77) | SCN9AGRIA1CACNG8CACNG2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | claimed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | claimed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | claimed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885GRIA1 1827/4885CACNG8 108/4885 |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885GRIA1 1827/4885CACNG8 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.